Close
The Hub is addressing the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.
Click here to read our 2021-2022 Annual Report
What will the Future Targeted Healthcare Manufacturing Hub deliver and achieve?
- By 2025 targeted biological medicines will transform the precision of healthcare prescription, improve patient care and quality of life.
- The current “one-size-fits-all” approach to drug development is being challenged by the growing ability to create stratified and personalised medicines targeted to specific sub-populations and even individuals.
- Without significant manufacturing and supply innovations, the promise of targeted healthcare will remain inaccessible for many. The impact on health and well-being is profound.
- The Hub will be the first globally recognised consortium for the creation, delivery and dissemination of innovative manufacturing research, underpinning cost-effective, robust manufacture, supply and delivery of targeted therapies.
UCL Hub Collaboration and Deliverables
The Hub will work with its network of users and academics to deliver the vision, with the core research focusing on:
- Grand Challenge 1: Transforming supply chain management and economics for targeted biotherapeutics with novel computational decision-support tools
- Grand Challenge 2: Sustainable manufacturing for future targeted biotherapeutics with novel bioprocesses, analytics and control algorithms
This paradigm shift in manufacturing practice will provide the manufacturing infrastructure needed for sustainable healthcare.
Research Impact
The benefits of the Hub extend beyond the users who have co-developed the proposal. Our innovations will move the reality of targeted healthcare forward significantly, by identifying the technological and logistical solutions. Targeted interventions will provide a step change for many patients in terms of widened access to new treatments. The range of targets is huge and includes treatments for cancers and the re-programming of degenerative disorders such as dementia. This is a radical new opportunity for the industry. The Hub will deliver the process innovations to enable the rapid and economic development of new clinical medicines and promises a new horizon for the sector.
UCL Biochemical Engineering has an outstanding track record and is a world leader in bioprocess research across a range of sectors. UCL’s Future Targeted Healthcare Manufacturing Hub engages leading academics across the UK as Spokes. This national asset is valued in excess of £20M over 7 years (2017–2023).
The Hub will address the manufacturing, business and regulatory challenges to ensure that new targeted biological medicines can be developed quickly and manufactured at a cost affordable to society.
The research will span stratified protein medicines targeted to particular patient groups through to truly personalised cell-based medicines.
The Hub is unique in the biomanufacturing space, and is being supported by a large number of the leading manufacturers and suppliers in the biotherapeutics industry and non-governmental associations.
How can stratified proteins and personal cell therapies achieve success in manufacturing and business?
The benefits of the Hub extend beyond the users who have co-developed the proposal. Our innovations will move the reality of targeted healthcare forward significantly, by identifying the technological and logistical solutions. Targeted interventions will provide a step change for many patients in terms of widened access to new treatments. The range of targets is huge and includes treatments for cancers and the re-programming of degenerative disorders such as dementia. This is a radical new opportunity for the industry. The Hub will deliver the process innovations to enable the rapid and economic development of new clinical medicines and promises a new horizon for the sector.
For more information on the Hub, collaboration and how join the industrial consortium please contact us at:
